Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | trypanothione reductase | 0.004 | 0.2529 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0014 | 0.0312 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0014 | 0.0312 | 0.5 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0091 | 0.6874 | 0.8837 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2108 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0101 | 0.7738 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.2108 | 0.1853 |
Brugia malayi | hypothetical protein | 0.0035 | 0.2108 | 0.8335 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0035 | 0.2108 | 0.7938 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.004 | 0.2574 | 1 |
Leishmania major | trypanothione reductase | 0.004 | 0.2529 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0035 | 0.2108 | 0.7938 |
Plasmodium falciparum | thioredoxin reductase | 0.004 | 0.2529 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0014 | 0.0312 | 0.5 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0091 | 0.6874 | 0.8837 |
Loa Loa (eye worm) | thioredoxin reductase | 0.004 | 0.2529 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2108 | 0.5 |
Brugia malayi | glutathione reductase | 0.004 | 0.2529 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2108 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.004 | 0.2529 | 1 |
Treponema pallidum | NADH oxidase | 0.0014 | 0.0312 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.004 | 0.2574 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.004 | 0.2529 | 0.2985 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0091 | 0.6874 | 0.8837 |
Loa Loa (eye worm) | glutathione reductase | 0.004 | 0.2529 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0035 | 0.2108 | 0.1853 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0014 | 0.0312 | 0.5 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0014 | 0.0312 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0014 | 0.0312 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.004 | 0.2529 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.004 | 0.2529 | 1 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0014 | 0.0312 | 0.1234 |
Toxoplasma gondii | thioredoxin reductase | 0.004 | 0.2529 | 1 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0091 | 0.6874 | 0.8837 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0014 | 0.0312 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0014 | 0.0312 | 0.5 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0091 | 0.6874 | 0.8837 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0101 | 0.7738 | 1 |
Brugia malayi | Thioredoxin reductase | 0.004 | 0.2529 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0101 | 0.7738 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0091 | 0.6874 | 0.8837 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.2108 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0101 | 0.7738 | 1 |
Plasmodium falciparum | glutathione reductase | 0.004 | 0.2529 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0014 | 0.0312 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.